Eric Rovner to Botulinum Toxins, Type A
This is a "connection" page, showing publications Eric Rovner has written about Botulinum Toxins, Type A.
Connection Strength
2.035
-
Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment. J Urol. 2016 Sep; 196(3):801-8.
Score: 0.521
-
Chapter 6: Practical aspects of administration of onabotulinumtoxinA. Neurourol Urodyn. 2014 Jul; 33 Suppl 3:S32-7.
Score: 0.456
-
OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013 Nov; 32(8):1109-15.
Score: 0.414
-
Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011 Apr; 30(4):556-62.
Score: 0.362
-
New treatments for incontinence. Adv Chronic Kidney Dis. 2015 Jul; 22(4):279-88.
Score: 0.122
-
Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2016 06; 35(5):595-600.
Score: 0.120
-
Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence. Neurourol Urodyn. 2019 02; 38(2):825-837.
Score: 0.039